1 / 4

Enzalutamide Has The Potential For Treating COVID-19

Enzalutamide, typically used to treat prostate cancer could be explored for treating patients with COVID-19. Researchers found that, as a type of testosterone-blocker, enzalutamide also reduced the ability of the SARS-CoV-2 coronavirus to infect lung cells in the lab.

sunnyfang1419
Download Presentation

Enzalutamide Has The Potential For Treating COVID-19

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Huateng Pharma https://en.huatengsci.com Enzalutamide Has The Potential For Treating COVID-19 Enzalutamide, typically used to treat prostate cancer could be explored for treating patients with COVID-19. Researchers found that, as a type of testosterone-blocker, enzalutamide also reduced the ability of the SARS-CoV-2 coronavirus to infect lung cells in the lab. This work is carried out by cancer researchers at Imperial College London and the University of Essex. It is part of a larger effort to find existing drugs that can block COVID-19 by reducing the ability of the virus to enter cells. The team said that the study adds more and more evidence from groups around the world to support further clinical trials to evaluate the efficacy of drugs called anti-androgens in the treatment of COVID-19 patients.

  2. Huateng Pharma https://en.huatengsci.com On July 1, their findings was published in the journal Nature Communications titled: The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells. Blocking infection SARS-CoV-2 is the virus that causes COVID-19. It has been proven to attack multiple organs in the body, but it is most destructive to the lungs. In the latest study, researchers focused on one of the proteins used by viruses to enter lung cells, called TMPRSS2, to see if reducing levels could block infection. It is known that male sex hormones or androgens increase the level of TMPRSS2 in a variety of tissues, most notably in the prostate. But drugs used to treat prostate cancer can block androgens, so they can counter the increase in TMPRSS2 and may provide a new treatment option for exploring COVID-19. The research team, co-led by Imperial's Professor Charlotte Bevan and Dr. Greg Brooke from Essex, found that the androgen-blocking drug enzalutamide (a well-tolerated drug widely used in advanced prostate cancer) reduced the level of TMPRSS2 in human lung cells cultured in the lab. Fig. 1: TMPRSS2 is an androgen-regulated gene in cells from different tissues.

  3. Huateng Pharma https://en.huatengsci.com Importantly, they found that this treatment significantly reduced the entry of SARS-CoV-2 into lung cells. The researchers stated that their study adds to the growing body of evidence from groups around the world and supports further clinical trials to evaluate the efficacy of antiandrogens as a potential treatment for COVID-19. Potential treatment Professor Charlotte Bevan, from the Department of Surgery & Cancer said: “This research not only supports further clinical investigation on these prostate cancer drugs, but also suggests other drugs we can test that may be useful for COVID-19 work. As we have learnt from cancer, it is important to have a range of drugs available in the armory. The advantage of drugs that have been tried and tested and approved in other diseases is that they can be reused in this way relatively quickly. " Dr. Greg Brooke, from the School of Life Sciences at the University of Essex explained: "Compared with women, men are more likely to experience severe discomfort and die from COVID-19. This suggests that the male sex hormone androgen may play a role in SARS-CoV-2 severity. For many years I have been studying the role of androgens in cancer, so I can use this knowledge to investigate whether anti-androgen drugs used to treat prostate cancer can reduce SARS-CoV-2 infection.” "We demonstrated that these drugs reduce the ability of the virus to enter the lungs. Therefore, our data supports clinical trials to investigate whether antiandrogens can reduce the severity of COVID-19 in people infected with the virus." added Dr. Greg Brooke. Two clinical trials evaluating anti-androgen therapy for COVID-19 have been conducted in the United States and Sweden, with early findings expected later this year. Huateng Pharma is a professional manufacturer committed to suppling many kinds of pharmaceutical intermediates. We supply kinds of anti-viral intermediates such as remdesivir intermediates which are used for treating COVID-19. We also supply prostate cancer drug Enzalutamide and its intermediates with best price and high quality. 1 API Enzalutamide View Details CAS No. 915087-33-1 2 Enzalutamide Intermediates 2-Aminoisobutyric acid CAS No. 62-57-7 View Details 3 Enzalutamide Intermediates 4-Bromo-2-fluorobenzoic acid CAS No. 112704-79-7 View Details

  4. Huateng Pharma https://en.huatengsci.com 4 Enzalutamide Intermediates 4-Bromo-2-fluoro-N-methylbenzamide CAS No. 749927-69-3​ View Details 5 Enzalutamide Intermediates Enzalutamide carboxylic acid CAS No. 1242137-15-0 View Details 6 Enzalutamide Intermediates 2-[3-Fluoro-4-(methylcarbamoyl)anilino]-2-methyl-propanoic acid CAS No. 1289942-66-0 View Details 7 Enzalutamide Intermediates 4-Isothiocyanato-2-(trifluoromethyl)benzonitrile CAS No. 143782-23-4 View Details Reference: The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells, Nature Communications (2021).

More Related